prazosin has been researched along with Lung Diseases, Obstructive in 8 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 51-year-old patient with COPD, obesity, and pulmonary hypertension underwent long-term prazosin therapy after a successful hemodynamic response to 1 mg of oral prazosin." | 7.68 | Long-term prazosin therapy for COPD pulmonary hypertension. ( Lewczuk, J; Piszko, P; Sobkowicz-Woźniak, B; Spikowski, J; Wrabec, K, 1992) |
| "The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)." | 7.67 | Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985) |
| "Prazosin was studied in 11 patients (10 men, 1 women) aged 63 +/- 7 years with advanced c." | 6.67 | [Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin]. ( Lewczuk, J; Palka, PS; Piszko, P; Porada, A; Sobkowicz-Woźniak, B; Spikowski, J; Szczygielski, J; Trzesicka, M; Wrabec, K, 1990) |
| " This doxazosin dosage reduced the diastolic blood pressure on average from 103 to 91 mmHg (P = 0." | 5.28 | Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. ( Biernacki, W; Flenley, DC, 1989) |
| "A single dose of capoten (25 mg) and prazosin (I mg) was given to 82 patients with stable pulmonary hypertension and chronic non-specific pulmonary diseases and to 34 patients with the above condition and arterial hypertension." | 5.06 | [Pharmacologic effects of peripheral vasodilators in patients with secondary pulmonary hypertension]. ( Abrosimov, AG; Belov, AM; Kukes, VG; Nasyrov, ShN; Tsoĭ, AN, 1989) |
| " In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking." | 4.78 | Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991) |
| "A 51-year-old patient with COPD, obesity, and pulmonary hypertension underwent long-term prazosin therapy after a successful hemodynamic response to 1 mg of oral prazosin." | 3.68 | Long-term prazosin therapy for COPD pulmonary hypertension. ( Lewczuk, J; Piszko, P; Sobkowicz-Woźniak, B; Spikowski, J; Wrabec, K, 1992) |
| "The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)." | 3.67 | Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985) |
| "Prazosin was studied in 11 patients (10 men, 1 women) aged 63 +/- 7 years with advanced c." | 2.67 | [Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin]. ( Lewczuk, J; Palka, PS; Piszko, P; Porada, A; Sobkowicz-Woźniak, B; Spikowski, J; Szczygielski, J; Trzesicka, M; Wrabec, K, 1990) |
| " This doxazosin dosage reduced the diastolic blood pressure on average from 103 to 91 mmHg (P = 0." | 1.28 | Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. ( Biernacki, W; Flenley, DC, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruynzeel, PL | 1 |
| Hamelink, ML | 1 |
| Kok, PT | 1 |
| van der Vet, AP | 1 |
| Kreukniet, J | 1 |
| Lewczuk, J | 3 |
| Sobkowicz-Woźniak, B | 2 |
| Piszko, P | 2 |
| Spikowski, J | 2 |
| Wrabec, K | 3 |
| Taylor, SH | 1 |
| Porada, A | 1 |
| Trzesicka, M | 1 |
| Palka, PS | 1 |
| Szczygielski, J | 1 |
| Biernacki, W | 1 |
| Flenley, DC | 1 |
| Kukes, VG | 1 |
| Tsoĭ, AN | 1 |
| Abrosimov, AG | 1 |
| Nasyrov, ShN | 1 |
| Belov, AM | 1 |
| Vik-Mo, H | 1 |
| Walde, N | 1 |
| Jentoft, H | 1 |
| Halvorsen, FJ | 1 |
2 reviews available for prazosin and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Efficacy of doxazosin in specific hypertensive patient groups.
Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin | 1991 |
[Value of vasodilator agents in the treatment of diseases with pulmonary hypertension caused by chronic obstructive lung diseases].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1991 |
2 trials available for prazosin and Lung Diseases, Obstructive
| Article | Year |
|---|---|
[Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin].
Topics: Administration, Oral; Aged; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructiv | 1990 |
[Pharmacologic effects of peripheral vasodilators in patients with secondary pulmonary hypertension].
Topics: Adolescent; Adult; Aged; Captopril; Clinical Trials as Topic; Hemodynamics; Humans; Hypertension, Pu | 1989 |
4 other studies available for prazosin and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Alpha 2-adrenergic receptors on intact human platelets of normal individuals and chronic obstructive lung disease patients.
Topics: Blood Platelets; Epinephrine; Humans; Lung Diseases, Obstructive; Phentolamine; Prazosin; Receptors, | 1984 |
Long-term prazosin therapy for COPD pulmonary hypertension.
Topics: Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middle Aged; Obesity; Prazosin; R | 1992 |
Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Asthma; Blood Pressure; Doxazosin; Female; Forced Expirat | 1989 |
Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale.
Topics: Administration, Oral; Aged; Carbon Dioxide; Chronic Disease; Female; Hemodynamics; Humans; Hypertens | 1985 |